Health Care [ 9/12 ] | Biotechnology [ 37/73 ]
NASDAQ | Common Stock
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.66 Increased by +20.48% | -0.74 Increased by +10.81% |
| May 12, 25 | -0.79 Decreased by -12.86% | -0.98 Increased by +19.39% |
| Feb 12, 25 | -0.98 Decreased by -60.66% | -1.08 Increased by +9.26% |
| Nov 11, 24 | -1.13 Decreased by -98.25% | -0.83 Decreased by -36.14% |
| Aug 13, 24 | -0.83 Decreased by -167.74% | -0.70 Decreased by -18.57% |
| May 9, 24 | -0.70 Decreased by -37.25% | -0.67 Decreased by -4.48% |
| Mar 21, 24 | -0.61 Increased by +64.94% | -0.82 Increased by +25.61% |
| Nov 7, 23 | -0.57 | -0.76 Increased by +25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -43.27 M Decreased by -5.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -42.21 M Decreased by -33.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 34.00 K Increased by +N/A% | -48.95 M Decreased by -100.69% | Decreased by -143.96 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -56.34 M Decreased by -147.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -41.01 M Decreased by -237.81% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -31.51 M Decreased by -149.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -24.39 M Decreased by -168.81% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -22.76 M Decreased by -240.82% | Decreased by N/A% Decreased by N/A% |